Today: 22 March 2026
Subscribe
Browse Category

NYSE:LLY 13 January 2026 - 18 January 2026

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly shares closed Friday at $1,038.40, up 0.5% after trading between $1,019 and $1,049.83. Investors are watching for FDA decisions on Lilly’s obesity pill and tracking early prescription data as Novo Nordisk’s Wegovy pill posts strong initial sales. U.S. markets will be closed Monday, reopening Tuesday. Lilly’s next earnings call is scheduled for February 4.
18 January 2026
··
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly shares rose 0.5% to $1,038.40 Friday as the FDA set April 10 as the new target date for a decision on its experimental weight-loss pill. The agency delayed review timelines for several drugs, including Lilly’s, under its fast-track program. Novo Nordisk’s new Wegovy pill saw about 3,071 U.S. prescriptions in its first four days, according to IQVIA data.
17 January 2026
··
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk shares surged 6.5% in Copenhagen and 9.1% in New York after early U.S. prescription data showed 3,071 Wegovy pill scripts filled in four days. Britain approved a higher maximum dose of Wegovy for obesity patients. A Texas compounding pharmacy sued Novo and Eli Lilly over alleged market dominance. Novo called the lawsuit “without merit.”
17 January 2026
···
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly shares rose 0.5% in after-hours trading after the FDA delayed its decision on the company’s obesity drug orforglipron to April 10. Lilly and Novo Nordisk face a lawsuit from Texas-based Strive Specialties, which alleges both companies restricted access to cheaper compounded versions of GLP-1 drugs. Lilly also disclosed a 10% stake in Aktis Oncology.
17 January 2026
··
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly shares fell 3.8% premarket to $1,033 after FDA documents set an April 10 decision date for its weight-loss pill under a fast-track program. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging efforts to block cheaper compounded GLP-1 drugs. Novo Nordisk shares dropped 3%. Investors await further FDA guidance and Lilly’s Feb. 4 earnings call.
16 January 2026
··
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly shares fell 3.8% to $1,032.97 in after-hours trading after the FDA delayed its decision on the company’s obesity pill to April 10. A Texas compounding pharmacy filed a new lawsuit against Lilly and Novo Nordisk, alleging efforts to block access to cheaper alternatives. Investors are watching Lilly’s Feb. 4 earnings call and the FDA’s April decision as key dates.
15 January 2026
··
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Eli Lilly shares fell 4.7% to $1,022.50 after Reuters reported the FDA delayed its decision on the company’s experimental weight-loss pill to April 10. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging anticompetitive practices tied to GLP-1 drugs. Novo Nordisk shares dropped 3.6%. Investors await Lilly’s Feb. 4 earnings for updates on the pill’s timeline and legal risks.
15 January 2026
·
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly shares fell about 0.3% in after-hours trading Wednesday after the FDA asked drugmakers to remove suicide-risk warnings from GLP-1 weight-loss drugs. The agency found no link between the drugs and increased suicide risk. Investors are watching Lilly’s plans for its oral obesity drug, orforglipron, which could launch soon at a $150 monthly price.
15 January 2026
··
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
14 January 2026
·····
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly shares fell about 0.4% Wednesday after the FDA ordered drugmakers to remove suicidality warnings from obesity drugs including Zepbound. The FDA said its review found no increased risk of suicidal thoughts with GLP-1 drugs. Investors are watching for updates on Lilly’s oral obesity pill ahead of the Feb. 4 earnings call.
14 January 2026
···
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly shares fell 0.4% after hours to $1,077.19 as the FDA told drugmakers to remove suicide warnings from GLP-1 weight-loss drugs, including Lilly’s Zepbound. At the JPMorgan Healthcare Conference, Lilly and rivals pitched new obesity pills and longer-acting shots, with Lilly targeting a second-quarter U.S. approval for its oral drug. Amgen and Novo Nordisk highlighted new data and launches in the crowded obesity market.
14 January 2026
··
Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention

Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention

Nvidia shares slipped 0.04% to $184.87 after hours Tuesday following reports China is restricting approvals for H200 AI chip purchases. Nvidia denied requiring upfront payment from Chinese buyers. The company also announced a $1 billion healthcare AI lab with Eli Lilly and new partnerships, but traders remain focused on China’s impact on chip demand.
13 January 2026
···
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly shares rose 0.2% after the FDA asked drugmakers to remove suicide-related warnings from GLP-1 weight-loss drugs. Lilly’s R&D chief said the company plans a rapid global launch of its oral obesity drug orforglipron, priced at $150 a month. Investors are watching for increased pill competition and the FDA’s upcoming decision.
13 January 2026
···
Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus

Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus

Nvidia said it will not require upfront payment for H200 AI chips, countering reports of stricter terms for Chinese buyers. Shares edged up 0.03% to $184.94 in early New York trading. Investors remain focused on China sales and the company’s Feb. 25 earnings for updates on demand and margins. Chip sector peers posted mixed results as U.S. inflation data met forecasts.
13 January 2026
····
1 2 3 4 5 6 … 12

Stock Market Today

  • Abbott Laboratories Valuation Faces Scrutiny Amid Recent Share Price Volatility
    March 22, 2026, 10:19 AM EDT. Abbott Laboratories (ABT) has experienced recent share price weakness, sparking a reassessment of its valuation. Trading at $105.46, the stock shows a 6.02% gain over 30 days but reflects mixed longer-term returns, with a 15.08% year-to-date rise against a modest 5-year total shareholder return of 5.34%. Simply Wall St's analysis estimates a fair value of $113.88, suggesting an approximate 36% intrinsic discount and potential undervaluation. Despite a P/E ratio of 28.3x above the US Medical Equipment industry average, Abbott's strong fundamentals, innovation focus, and diversified portfolio support its position as a growth stock with defensive traits. However, risks include regulatory challenges and margin pressure from costs and competition. Investors should balance these rewards and risks to inform their investment outlook on ABT.
Go toTop